RAPT Therapeutics stock (US74933X1090): OrbiMed files 13G/ A showing zero shares

RAPT Therapeutics is in focus after OrbiMed reported a Schedule 13G/A amendment showing no beneficial ownership of the company’s common stock.

RAPT Therapeutics is back on the radar after OrbiMed Advisors LLC filed an amended Schedule 13G/A that reported 0 shares and 0.0% ownership of the company’s common stock, according to StockTitan as of 05/16/2026. For US investors, the filing matters because it updates one of the more closely watched ownership disclosures for a Nasdaq-listed biotechnology name tied to drug development risk and financing sensitivity.

As of: 16.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: RAPT Therapeutics
• Sector/industry: Biotechnology
• Headquarters/country: United States
• Home exchange/listing venue: Nasdaq
• Trading currency: USD
• Key revenue drivers: Clinical-stage drug development and financing-related corporate activity

RAPT Therapeutics: core business model

RAPT Therapeutics is a clinical-stage biotechnology company focused on developing therapies for patients with inflammatory and oncology-related diseases. Companies in this segment usually do not rely on product sales in the near term, which means investor attention often shifts toward clinical milestones, cash runway, and shareholder registry changes rather than quarterly revenue trends.

The latest ownership filing does not change the company’s operating profile, but it does add a new market datapoint around institutional positioning. In biotech, even passive ownership updates can matter because they help investors gauge how large holders are moving around the name, especially when financing conditions are tight and sentiment can move quickly on limited news.

Main revenue and product drivers for RAPT Therapeutics

For RAPT Therapeutics, the main value drivers are pipeline progress, regulatory milestones, and the company’s ability to fund development through capital markets or partnerships. That makes it different from large-cap drugmakers with recurring commercial revenue, and it also means share performance can be driven more by news flow than by current sales.

The company’s shares are relevant for US investors because they trade on Nasdaq and sit in a segment of the market that is sensitive to trial updates, funding news, and institutional filings. In practical terms, that combination can create sharp price reactions even when the underlying news is procedural rather than operational.

Conclusion

RAPT Therapeutics is not being moved by an earnings release or product approval here, but the amended ownership filing still gives investors a fresh look at institutional exposure to the stock. For a small biotechnology company, that can matter as much as headline operating news because ownership patterns often influence trading interest and liquidity. The filing is neutral on fundamentals, but it is a timely update for investors tracking the name on Nasdaq.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.